MedPath

Voraxaze

These highlights do not include all the information needed to use VORAXAZE safely and effectively. See full prescribing information for VORAXAZE. VORAXAZE (glucarpidase) for injection, for intravenous use Initial U.S. Approval: 2012

Approved
Approval ID

acaef5a6-b740-40e3-8ffe-74a75c74745c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 18, 2022

Manufacturers
FDA

BTG International Inc.

DUNS: 617382395

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

glucarpidase

PRODUCT DETAILS

NDC Product Code50633-210
Application NumberBLA125327
Marketing CategoryC73585
Route of AdministrationINTRAVENOUS
Effective DateOctober 24, 2018
Generic Nameglucarpidase

INGREDIENTS (4)

GLUCARPIDASEActive
Quantity: 1000 [USP'U] in 1 1
Code: 2GFP9BJD79
Classification: ACTIB
LACTOSE MONOHYDRATEInactive
Quantity: 10 mg in 1 1
Code: EWQ57Q8I5X
Classification: IACT
ZINC ACETATEInactive
Quantity: 0.002 mg in 1 1
Code: FM5526K07A
Classification: IACT
TROMETHAMINE HYDROCHLORIDEInactive
Quantity: 0.6 mg in 1 1
Code: 383V75M34E
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Voraxaze - FDA Drug Approval Details